These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

181 related items for PubMed ID: 12442064

  • 1. Combination-therapy with bedtime nph insulin and sulphonylureas gives similar glycaemic control but lower weight gain than insulin twice daily in patients with type 2 diabetes.
    Olsson PO, Lindström T.
    Diabetes Metab; 2002 Sep; 28(4 Pt 1):272-7. PubMed ID: 12442064
    [Abstract] [Full Text] [Related]

  • 2. Lower within-subject variability of fasting blood glucose and reduced weight gain with insulin detemir compared to NPH insulin in patients with type 2 diabetes.
    Haak T, Tiengo A, Draeger E, Suntum M, Waldhäusl W.
    Diabetes Obes Metab; 2005 Jan; 7(1):56-64. PubMed ID: 15642076
    [Abstract] [Full Text] [Related]

  • 3. Premeal insulin lispro plus bedtime NPH or twice-daily NPH in patients with type 2 diabetes: acute postprandial and chronic effects on glycemic control and cardiovascular risk factors.
    Ceriello A, Del Prato S, Bue-Valleskey J, Beattie S, Gates J, de la Peña A, Malone J.
    J Diabetes Complications; 2007 Jan; 21(1):20-7. PubMed ID: 17189870
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Less weight gain and hypoglycaemia with once-daily insulin detemir than NPH insulin in intensification of insulin therapy in overweight Type 2 diabetes patients: the PREDICTIVE BMI clinical trial.
    Fajardo Montañana C, Hernández Herrero C, Rivas Fernández M.
    Diabet Med; 2008 Aug; 25(8):916-23. PubMed ID: 18959604
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. [Medication use in diabetes mellitus (VI). Economics and effectiveness of insulin and sulfonyl-urea combination therapy compared with conventional two daily doses].
    Costa B, Estopá A, Borrás J, Sabaté A.
    Med Clin (Barc); 1998 Nov 07; 111(15):568-72. PubMed ID: 9859089
    [Abstract] [Full Text] [Related]

  • 8. Efficacy of insulin and sulfonylurea combination therapy in type II diabetes. A meta-analysis of the randomized placebo-controlled trials.
    Johnson JL, Wolf SL, Kabadi UM.
    Arch Intern Med; 1996 Feb 12; 156(3):259-64. PubMed ID: 8572835
    [Abstract] [Full Text] [Related]

  • 9. Effect of combination therapy of troglitazone and sulphonylureas in patients with Type 2 diabetes who were poorly controlled by sulphonylurea therapy alone.
    Iwamoto Y, Kosaka K, Kuzuya T, Akanuma Y, Shigeta Y, Kaneko T.
    Diabet Med; 1996 Apr 12; 13(4):365-70. PubMed ID: 9162613
    [Abstract] [Full Text] [Related]

  • 10. Improved glycaemic control with BIAsp 30 in insulin-naïve type 2 diabetes patients inadequately controlled on oral antidiabetics: subgroup analysis from the IMPROVE study.
    Wenying Y, Benroubi M, Borzi V, Gumprecht J, Kawamori R, Shaban J, Shah S, Shestakova M, Ligthelm R, Valensi P, IMPROVE Study Group Expert Panel.
    Curr Med Res Opin; 2009 Nov 12; 25(11):2643-54. PubMed ID: 19751116
    [Abstract] [Full Text] [Related]

  • 11. Improved glycaemic control of thrice-daily biphasic insulin aspart compared with twice-daily biphasic human insulin; a randomized, open-label trial in patients with type 1 or type 2 diabetes.
    Clements MR, Tits J, Kinsley BT, Råstam J, Friberg HH, Ligthelm RJ.
    Diabetes Obes Metab; 2008 Mar 12; 10(3):229-37. PubMed ID: 18269638
    [Abstract] [Full Text] [Related]

  • 12. Inhaled insulin as adjunctive therapy in subjects with type 2 diabetes failing oral agents: a controlled proof-of-concept study.
    Hausmann M, Dellweg S, Osborn C, Heinemann L, Buchwald A, Rosskamp R, Genova P, Heise T.
    Diabetes Obes Metab; 2006 Sep 12; 8(5):574-80. PubMed ID: 16918593
    [Abstract] [Full Text] [Related]

  • 13. Insulin detemir compared with NPH insulin in children and adolescents with Type 1 diabetes.
    Robertson KJ, Schoenle E, Gucev Z, Mordhorst L, Gall MA, Ludvigsson J.
    Diabet Med; 2007 Jan 12; 24(1):27-34. PubMed ID: 17227321
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Type II diabetic subjects with secondary failure: treatment with prebreakfast mixed ultralente and regular insulin with a sulfonylurea.
    Kabadi UM, Kabadi MU.
    J Fam Pract; 1991 Oct 12; 33(4):349-53. PubMed ID: 1919450
    [Abstract] [Full Text] [Related]

  • 18. Comparison of bedtime NPH or preprandial regular insulin combined with glibenclamide in secondary sulfonylurea failure.
    Landstedt-Hallin L, Adamson U, Arner P, Bolinder J, Lins PE.
    Diabetes Care; 1995 Aug 12; 18(8):1183-6. PubMed ID: 7587856
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Daytime glibenclamide and bedtime NPH insulin compared to intensive insulin treatment in secondary sulphonylurea failure: a 1-year follow-up.
    Clauson P, Karlander S, Steen L, Efendic S.
    Diabet Med; 1996 May 12; 13(5):471-7. PubMed ID: 8737030
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.